Fused deep learning paradigm for the prediction of o6-methylguanine-DNA methyltransferase genotype in glioblastoma patients: A neuro-oncological investigation.

Journal: Computers in biology and medicine
PMID: 36621191

Abstract

BACKGROUND: The O6-methylguanine-DNA methyltransferase (MGMT) is a deoxyribonucleic acid (DNA) repairing enzyme that has been established as an essential clinical brain tumor biomarker for Glioblastoma Multiforme (GBM). Knowing the status of MGMT methylation biomarkers using multi-parametric MRI (mp-MRI) helps neuro-oncologists to analyze GBM and its treatment plan.

Authors

  • Sanjay Saxena
    Department of CSE, International Institute of Information Technology, Bhubaneswar, India.
  • Biswajit Jena
    Department of CSE, International Institute of Information Technology, Bhubaneswar, India.
  • Bibhabasu Mohapatra
    Department of Computer Science & Engineering, International Institute of Information Technology, Bhubaneswar, Odisha, India.
  • Neha Gupta
    Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Rae Bareli Road, Lucknow, 226025, India.
  • Manudeep Kalra
    Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, USA.
  • Mario Scartozzi
    Department of Radiology, A.O.U, di Cagliari-Polo di Monserrato s.s, 09124, Cagliari, Italy.
  • Luca Saba
    Department of Radiology, A.O.U., Italy.
  • Jasjit S Suri
    Advanced Knowledge Engineering Center, Global Biomedical Technologies, Inc., Roseville, CA, USA. Electronic address: jsuri@comcast.net.

Keywords

External Resources

Popular Topics
Recent Journals